Shift Bioscience is a pre-clinical biotech company targeting the root causes of aging to extend healthy lifespan.

Follow us on Twitter

Aging arises from dysfunction in several cellular processes interacting together, commonly referred to as the ‘hallmarks of aging’. Prominent geroscience companies are targeting different hallmarks of aging, but the question of which hallmark is more or less central to aging has remained a subject of debate.

The recent discovery and experimental use of a highly accurate aging biomarker (Horvath’s multi-tissue epigenetic aging clock) has revealed that some hallmarks have a significant impact on the aging clock whilst other hallmarks have little or no effect. It follows that targeting specific central hallmarks which have the greatest observed effect on the clock (mitochondrial dysfunction, cellular senescence) will have the greatest impact on slowing or reversing processes of aging.

We target one of these processes; loss of energy production due to damaged mitochondria. We have discovered small molecule drugs and tool molecules (we refer to these as Shift drugs) that restore mitochondrial function by shifting the ratio of mitochondrial genomes from damaged to healthy. This provides a novel and exciting approach to combatting diseases of aging, combatting aging itself and treating specific orphan diseases.



Between the ages of 20 and 70 our risk of death from disease increases exponentially. This leads to a matching exponential increase in healthcare costs. The 65+ age group incurs four to five times the health care costs of the under 65s. Globally, over-65s number 600m people today and this will increase to 1.2 billion by 2050. This inevitable rapid aging of the population will create an unsustainable burden on healthcare budgets. In the US this represents an additional $800 billion annual ‘tax’ that will need to be paid, either by insurers, taxpayer or patients themselves.

Today’s available therapies for age-related diseases deal with the symptoms but not with the underlying causes of disease. There is an urgent imperative to develop new therapies based on our rapidly-expanding knowledge of what causes aging at the molecular level.

New epigenetic tools have given scientists the ability to examine the hallmarks of aging and to determine which are root causes and which are consequences that sit downstream of these root causes. These new insights can be used to guide the development of a new generation of more effective therapies for age-related diseases.



During the past half-century, the advances in the prevention, diagnosis, and management of cardiovascular disease (CVD) have been nothing short of spectacular. Age-adjusted CVD-related deaths have declined by about two-thirds in industrialized nations. Heart failure (HF) is a notable exception to these encouraging trends. Annual hospital admissions for patients with a primary diagnosis of HF now exceed 1 million admissions per year in the US, and HF patients make more than 3m physician visits per year.

The costs of HF in the United States were estimated at US $39.2 billion per annum by the American Heart Association in 2010. The estimated lifetime cost of HF per individual patient is $110,000/year with more than 75% of this cost consumed by in-hospital care. Five-year mortality is approximately 50%, which is worse than that of many cancers.

Heart failure can be classified into two primary types with approximately equal prevalence: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Whilst there are some recently-approved drugs that are effective in treating HFrEF, there are no effective disease modifying drugs yet approved for either type of heart failure.



Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a rare mitochondrial disease caused by mutations in mtDNA inherited from the mother. Symptoms usually appear in childhood and become increasingly severe with age. The condition is systemic affecting many parts of the body, particularly the heart, brain and muscles.

We have selected MELAS as our first disease target because the root cause – mitochondrial dysfunction caused by mutations in mtDNA – is well understood with a high level of consensus among clinicians, and we have demonstrated strong proof-of-concept in pre-clinical studies.  We have been able to reduce the level of MELAS mtDNA mutations and restore cellular energetic function in fibroblast cells taken from MELAS patients.

Follow us on Twitter